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Summary
We have examined genomic DNA from 40 cases of au-
topsy-confirmed early-onset Alzheimer disease (EOAD)
(age at onset X65 years) that were all unselected for
family history. We have sequenced the 10 exons and
flanking intronic sequences of the presenilin-1 (PS-1)
gene for all 40 individuals. A single mutation, a deletion
of a G from the intron 4 splice-donor consensus se-
quence, was detected in two individuals in this study.
The mutation was associated with two shortened tran-
scripts, both with shifted reading frames resulting in pre-
mature-termination codons. All the PS-1 mutations de-
scribed elsewhere have been missense or in-frame splice
mutations, and recent data suggest that these result in
disease by gain-of-function or dominant-negative mech-
anisms. The mutation that we have identified is likely
to result in haploinsufficiency and would be most con-
sistent with other mutations acting in a dominant-neg-
ative manner. However, we cannot exclude the possi-
bility that the small amounts of truncated transcripts
exert a gain of function. Since no other mutations or
polymorphisms were detected in our patients, mutations
in the coding regions and splice consensus sequences of
PS-1 are likely to be rare in EOAD cases unselected for
family history.
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Introduction
Alzheimer disease (AD) is rare at !65 years of age, and
its prevalence at 55–64 years of age has been estimated
to be 0.2% (Ott et al. 1995). However, since the pro-
portion of the European population 35–64 years of age
is ∼3.5 times larger than that x65 years of age (World
Health Organization 1996, p. xxv), some reviewers have
suggested that AD presenting at !65 years of age may
account for as much as 15%–25% of the total number
of prevalent AD cases (Cruts et al. 1996; Sandbrink et
al. 1996), although we are not aware of a large, statis-
tically robust study that has formally computed these
data. The proportion of cases of early-onset AD (EOAD)
(defined by an arbitrary age cutoff of 60–65 years) that
are familial also does not appear to have been deter-
mined in large, epidemiologically based series, and re-
viewers’ estimates are within the range of 10%–50%
(Heston 1992; Van Broeckhoven 1995a; Sandbrink et
al. 1996). The majority of familial cases of EOAD are
thought to be due to mutations within the presenilin-1
(PS-1) gene (Cruts et al. 1996; Sandbrink et al. 1996),
presumably on the basis of impressions from linkage
studies of EOAD families. However, we are not aware
of published studies that have rigorously sequenced
PS-1 in unbiased selections of EOAD pedigrees. All the
PS-1 mutations described elsewhere have been missense
or in-frame splice mutations, and recent data suggest
that these result in disease either by acquisition of novel
deleterious functions (gain of function) (Van Broeck-
hoven 1995b) or by interference with the function of
the normal wild-type protein, thereby lowering its ac-
tivity (dominant negative). Both these mechanisms are
compatible with experiments showing that mice or cell
lines transfected with familial presenilin mutations have
increased production of the amyloidogenic 42-residue
amyloid b-peptide, whereas no such effect was seen
when the mice or the cell lines were transfected with the
wild-type gene (Duff et al. 1996; Scheuner et al. 1996;
Citron et al. 1997).
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For a disease with a comparatively late onset, the ab-
sence of a family history does not preclude the presence
of dominant mutations, since affected individuals may
die of other causes before they become demented. Fur-
thermore, a PS-1 mutation with variable penetrance has
been described (Rossor et al. 1996). Although other
studies are in progress (Van Broeckhoven et al. 1996),
there have been no large studies published that have
determined the proportion of EOAD cases (unselected
for family history) that carry PS-1 mutations. In this
study, we have examined genomic DNA from 40 cases
of autopsy-confirmed EOAD (age at onset X65 years)
that were all unselected for family history. We have se-
quenced the 10 exons and flanking intronic sequences
of PS-1 for all 40 individuals and have identified one
mutation within the splice-donor consensus sequence of
intron 4 in 2 individuals. Analysis of RNA extracted
from brain tissue with this mutation revealed that the
mutation was associated with two shortened transcripts,
both of which had shifted reading frames and premature-
termination codons.
Subjects and Methods
Subjects
Brain-tissue samples from 40 individuals with a neu-
ropathological diagnosis of AD, at autopsy, were ob-
tained from brain banks in England (13 from Cam-
bridge, 13 from London, 11 from Bristol, and 3 from
Southend). These cases were selected without reference
to family history.
DNA and RNA Extraction
Frozen brain tissue was stored at 70C and was ho-
mogenized in liquid nitrogen prior to phenolchloroform
DNA extraction. RNA was prepared by use of an
RNeasy Total RNA kit (Qiagen).
PCR and Sequence Analysis
Each exon of the PS-1 gene was amplified from ∼100
ng of genomic DNA by use of pairs of intronic primers.
Exons 3, 6, 8–10, and 12 were amplified by use of prim-
ers and conditions taken from the study by Hutton et
al. (1996). Exons 4, 5, 7, and 11 were amplified by use
of the following primers: exon 4—4-1, 5′-CGT TAC
CTT GAT TCT GCT GA-3′, and 4-2, 5′-GAC ATG CTG
TAA AGA AAA GCC-3′; exon 5—5-1, 5′-AAA TTC
TGT GTT GGA GGT GG-3′, and 5-2, 5′-ATA AGA
AGA ACA GGG TGG AAA-3′; exon 7—7-1, 5′-GGA
GCC ATC ACA TTA TTC TAA A-3′, and 7-2, 5′-AAC
AAA TTA TCA GTC TTG GGT T-3′; and exon 11—11-
1, 5′-GGT TGA GTA GGG CAG TGA TA-3′, and 11-
2, 5′-TTA AAG GGA CTG TGT AAT CAA A-3′. PCR
conditions for these primers were as follows: 50 mM
KCl; 10 mM Tris-HCl, pH 8.0, at room temperature;
1.5 mM MgCl2 (2.0 mM for exon 7); 0.01% gelatin;
30 ng of each primer; 250 mM of each dNTP; and 0.3
U of Taq polymerase (Gibco BRL). The cycle parameters
were 3 min initial denaturation at 94C, followed by 35
cycles of 94C for 30 s, 55C (54C for exon 11) for 30
s, and 72C for 1 min. Sequence templates were prepared
from PCR reactions that were purified by use of the
Wizard PCR preps DNA purification system (Promega).
Sequence reactions were performed, in both directions,
by use of the fmol DNA cycle-sequencing system (Pro-
mega), using PCR primers end-labeled with g-[32P]-
dATP. Sequence reactions from seven individuals were
analyzed on each 6% polyacrylamide gel and were vi-
sualized by autoradiography. On each gel, all seven G,
A, T, and C termination reactions were run adjacent to
each other, to allow quick and easy sequence
comparison.
Restriction Analysis
A putative mutation within the splice donor site of
intron 4 destroyed a PvuII restriction site, which allowed
confirmation of the sequence variant, by PCR and re-
striction analysis. In order to ascertain whether the var-
iant was a common polymorphism or a causative mu-
tation, we performed PCR and restriction digestion on
two anonymized control populations: one sample com-
prised 92 young people !17 years of age who were cho-
sen randomly from referrals to the Molecular Genetics
Laboratory of the East Anglian Medical Genetics Service
in Cambridge, and the second sample comprised 56 non-
demented individuals x84 years of age (Tysoe et al.
1997).
cDNA Analysis
cDNA was synthesized from RNA extracted from
brain tissue with and without the splice-site mutation,
by use of random hexamers (SuperScript Preamplifica-
tion System, Gibco BRL). PCR was performed by use
of primers 3-3F (5′-TGA GGA CAA CCA CCT GAG
CAA-3′) and 5-3R (5′-TGG CAG CAT TCA GAA TTG
AGT-3′) (located at positions 299–319 and 660–640,
respectively, according to the S182 mRNA sequence, ac-
cession number L42110). These primers amplified PCR
products of 362 bp (VRSQ amino acids) and 374 bp
(VRSQ), from wild-type transcripts, by use of the con-
ditions described for exon 7 (see PCR and Sequence
Analysis). PCR products were visualized on silver-
stained 10% polyacrylamide gels. Truncated PCR prod-
ucts were agarose-gel purified and reamplified by use of
primers 3-3F and 5-3R, prior to sequence analysis.
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Figure 1 Age at onset for EOAD cases studied. Age at death is
shown for individuals whose age at onset was not known.
Figure 2 Detection of splice-donor-site mutation, by direct sequence analysis of PS-1 exon 4/ intron 4 junction. A, G, A, T, and C reactions
were performed in reverse orientation by use of primer 4-2. We have indicated the complementary sequence (corresponding to the sense strand)
on the right side of panel A, with the 5′ end at the top. A heterozygous 1-bp deletion was detected in two individuals (lanes 2 and 7 of each
set of reactions), resulting in the loss of a G from the GT splice-donor consensus site of intron 4. Exonic and intronic sequences are represented
by uppercase and lowercase letters, respectively. The splice-site mutation destroys a PvuII restriction site (boxed). B, PCR analysis of PS-1 exon
4 and the flanking splice sites, to screen for the presence of the PvuII restriction site. Lanes “WT,” Individual lacking the splice-site mutation.
Lanes “MUT,” Individual heterozygous for the splice-site mutation. U  uncut; and C  cut.
Haplotype Analysis of Mutation Carriers
Haplotype analysis was performed by use of short-
tandem-repeat (STR) markers D14S1004 (alias
AFMa337zd5, 5 alleles, 192 bp) and D14S1028 (alias
AFMb345wc1, 11 alleles, 231 bp) flanking the PS-1 gene
(Cruts et al. 1995). PCR reactions were performed as
described previously (see PCR and Sequence Analysis),
with the exceptions that 1.0 mM MgCl2 was optimal
and 0.2 pmol of g-[32P]-dATP end-labeled PCR primer
was added to each reaction. The cycle parameters were
3 min initial denaturation, followed by 30 cycles of 94C
for 90 s, 58C (55C for D14S1028) for 90 s, and 72C
for 90 s. PCR products were analyzed on a 6% poly-
acrylamide gel and were visualized by autoradiography.
Results
We have examined 40 autopsy-confirmed EOAD
cases, obtained from brain banks in England, that were
not selected for family history. The age at onset (when
known) for these individuals was within the range of
44–65 years (fig. 1). One case had a positive family his-
tory of EOAD, although family details were only avail-
able for 5 of the 40 cases. Intronic PCR primers were
used to amplify and sequence all 10 exons and flanking
intronic sequences of PS-1, from genomic DNA from
these 40 individuals (see Subjects and Methods). A single
mutation was detected in two individuals, who were
found to carry a heterozygous 1-bp deletion within the
5′ splice donor site of intron 4 (fig. 2A).This mutation
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Figure 3 cDNA analysis of RNA extracted from brain tissue with and without the splice-donor-site mutation. PCR primers located in
exons 3 and 5 were used to amplify across exon 4. A cDNA sample without the mutation (lane 1) produced bands of 374 bp and 362 bp (top
arrow), corresponding to the full-length (VRSQ) and short (VRSQ) transcripts (i.e., exon 3 and the complete exon 4 spliced to exon 5).
Two shorter transcripts were detected in cDNA from individuals with the mutation (lanes 2 and 3): intermediate products of 205 bp (VRSQ)
and 193 bp (VRSQ), containing the first 82 bp of exon 4 (middle arrow), and shorter products of 123 bp (VRSQ) and 111 bp (VRSQ),
which completely lack exon 4 (bottom arrow). The sizes of these bands were precisely determined by sequence analysis (see fig. 4 and Results).
The box at the 3′ end of exon 3 represents the alternatively spliced VRSQ motif.
Figure 4 Genomic sequence of PS-1, showing mutant and ab-
normal splice sites. The coding sequence is in uppercase letters, and
the intronic sequence is in lowercase letters. Loss of the g (indicated
in boldface) from the 5′ splice donor of intron 4 led to abnormal
splicing events, which resulted in the removal of all (within boldface
square brackets) or part (within boldface parentheses) of exon 4, using
a cryptic splice site within exon 4, at position 82 (double underlined).
Alternatively spliced nucleotides at the 3′ end of exon 3 are indicated
in italics. The positions of primers 3-3F and 5-3R are underlined.
resulted in the loss of the G from the GT consensus
sequence and was confirmed, since it destroyed a PvuII
restriction site present in the wild-type genomic sequence
(fig. 2B). No other mutations or polymorphisms were
detected in the coding regions and flanking intronic
regions in any of the individuals. It is unlikely that we
have missed any mutations, since the sequence reactions
were fully optimized, which produced unambiguous se-
quences in both forward and reverse orientations. In
order to confirm that this splice-site variant was not a
common polymorphism, PCR and restriction analyses
using PvuII were performed and failed to detect this
variant in any of the 296 normal chromosomes tested
(data not shown).
The most common outcome of a mutation in the in-
variant GT splice donor site is that the preceding exon
is skipped during RNA processing, although it is also
possible that an alternative, cryptic splice site(s) may be
activated (Maquat 1996). These possibilities were ex-
amined by analysis of cDNA reverse transcribed from
RNA extracted from brain samples with and without
the mutation, by use of PCR primers located in exons
3 and 5, which amplified across exon 4 (fig. 3). This
region includes the coding sequence for the VRSQ motif
(amino acids 26–29) at the end of exon 3, which un-
dergoes alternative splicing and normally results in a
mixture of cDNAs with (VRSQ) and without
(VRSQ) this 12-bp motif (Alzheimer’s Disease Collab-
orative Group 1995; Cruts et al. 1995). cDNA samples
without the mutation produced bands corresponding to
full-length (VRSQ) and short (VRSQ) transcripts
(i.e., exon 3 and the complete exon 4 spliced to exon 5)
(fig. 3). However, amplification of the same region from
cDNA prepared from brain samples with the mutation
produced the two full-length products and two truncated
products, which were present in low abundance. The
truncated products were gel purified and reamplified by
use of the same PCR primer pair. Sequence analysis re-
vealed that the shortened products were abnormally
spliced transcripts lacking all or part of exon 4 (fig. 4).
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Figure 5 Putative amino acid sequence of wild-type PS-1 and
truncated protein products, resulting from the introduction of pre-
mature-termination codons. All three transcripts have a common N-
terminal region (amino acids 1–30). The full-length PS-1 transcript
codes for a protein product of 467 amino acids (amino acids 1–100
are shown; top line). However, two shorter transcripts (shown in fig.
4) code for truncated protein products of 77 (middle line) and 70
(bottom line) amino acids, which diverge from the wild-type sequence
at codons 57 and 31, respectively.
Figure 6 Pedigree of individual with a splice mutation and a family history of EOAD. The individual carrying the splice mutation is
indicated by the arrow. All affected individuals (except II.8) died of AD in their early 40s.
The smallest transcript represented an mRNA lacking
the entire exon 4, whereas the intermediate transcript
used a cryptic splice site within exon 4 (at position 82)
to produce a transcript containing only part of exon 4
(fig. 4). Inspection of the cryptic splice donor site
(CAGG/gtaact) revealed a similarity to the consensus
splice donor site (CAG/gtaagt) (Maquat 1996) (fig. 4).
This data indicate that alternative sites that normally are
not recognized as splice donors may be utilized in the
absence of an intact consensus splice donor site. Both
of these shortened transcripts resulted in frameshifts,
leading to the introduction of premature-termination co-
dons (fig. 5). The apparent absence of the reverse-tran-
scriptase–PCR product corresponding to the shortest
mutant transcript lacking exon 4, in one of the cases,
may be due to its low abundance, since it was the rarest
transcript (fig. 3).
These results are unlikely to be artifactual, since these
bands were not seen in cDNA from a normal brain or
a neuroblastoma cell line, whereas they were observed
in both brains carrying the splice-site mutation. On mul-
tiple occasions, the experiments were performed with
both oligo-dT– and random-primed reverse transcrip-
tion. Both individuals carrying the mutation were from
the same region of East Anglia: one individual had a
positive family history of EOAD (fig. 6), but no family-
history data were available for the second case. The age
at onset was not documented for either of the two cases;
however, the case with the positive family history died
at 45 years of age, whereas the second case died in his
40s. We amplified genomic DNA from both patients for
the STR markers flanking the PS-1 gene, D14S1004 and
D14S1028 (Cruts et al. 1995), and for the PS-1 intron
8 polymorphism (Wragg et al. 1996); in each case, one
allele was shared, which is compatible with the mutant
chromosomes being related. We could not formally show
cosegregation of this mutation, with familial AD, owing
to lack of DNA from relatives.
Both patients carrying the splice-site mutation were
examined by an experienced neuropathologist (J.X.),
who made the diagnosis of EOAD. Microscopical ex-
amination of brain tissue from patient 1 revealed con-
siderable loss of nerve cells from the pyramidal layer of
the hippocampal formation and from the adjacent en-
torhinal cortex. Nerve-cell loss was also apparent in nu-
merous sections from the cerebral neocortex, with a sec-
ondary spongiosis of the neutropil in the superficial
layers. There was evidence of nerve-cell loss in the brain
stem, in the raphe nuclei of the midbrain, and in the
pons. The locus coeruleus showed marked nerve-cell
loss, but the substantia nigra was normally populated.
Sections of the cerebellum were normal. Modified Biel-
schowsky silver-impregnation techniques identified nu-
merous neuritic plaques and neurofibrillary tangles in
the hippocampus, adjacent to the entorhinal cortex and
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all areas of the cerebral neocortex. Neurofibrillary tan-
gles were present in the raphe nuclei of the brain stem,
the locus coeruleus of the pons, and also the peduncu-
lopontine and lateral tegmental nuclei in the lower mid-
brain/upper pons. There was no histological evidence of
cerebral amyloid angiopathy. The brain tissue had the
appearance of AD, with no evidence of other coinci-
dental pathological processes.
Neuropathological examination of brain tissue from
patient 2 revealed that sections of both hippocampus/
parahippocampal gyrus and all areas of the cerebral ne-
ocortex showed extensive AD-type pathology. There was
evidence of nerve-cell loss, most obvious in the CA1
region of the hippocampal pyramidal cell layer and in
the superficial layers of the cerebral neocortex, with sec-
ondary spongiosis. Numerous intraneuronal neurofi-
brillary tangles, extensive neuritic plaque formation,
and, in some areas (hippocampus), evident granulovac-
uolar degeneration were also associated with the exten-
sive neuropil thread formation. Pick bodies and cortical
Lewy bodies were absent. There was cell loss from the
pigmented nuclei of the brain stem, namely, the sub-
stantia nigra and locus coeruleus. In surviving nerve
cells, neurofibrillary tangles were identified within both
of these structures. Neurofibrillary tangles also were
present in the raphe nuclei of the brain stem. Substantia-
nigra Lewy bodies were absent. There was no evidence
of cerebral angiopathy or of cerebral infarctions. A final
diagnosis of severe AD was made on the basis of these
observations.
Discussion
All the PS-1 mutations described elsewhere have been
missense (Cruts et al. 1996) or in-frame splice mutants
(Perez-Tur et al. 1995), which has led to the suggestion
that these mutations result in disease by acquisition of
novel deleterious functions (Scheuner et al. 1996), either
by gain-of-function or dominant-negative mechanisms.
As far as we are aware, this is the first report of a frame-
shift mutation in PS-1, which is most likely to result in
PS-1 haploinsufficiency. In addition, the frameshifted
messages were less abundant than the full-length mes-
sage (fig. 3). This phenomenon, often associated with
mRNA-containing premature truncations, is thought to
be due to the decreased half-life of the mutant message
(Maquat 1996). The possibility that reduced PS-1 activ-
ity may contribute to EOAD is supported by in vivo
studies showing decreased function of PS-1 missense mu-
tations in Caenorhabditis elegans: whereas wild-type hu-
man PS-1 can substitute for its homologue in C. elegans
(the SEL-12 protein), PS-1 missense mutations have im-
paired ability to rescue the mutant phenotype in C. ele-
gans with reduced SEL-12 activity (Levitan et al. 1997).
The mutation that we have observed alters the GT
splice-donor sequence at the 5′ end of intron 4. This GT
sequence was conserved in 100% of introns surveyed by
Mount (1982) and is considered to be normal for intron
removal (Maquat 1996). Since the mutation results in
GT being replaced with TA, at the 5′ end of the intron
(fig. 2), we believe that it is extremely unlikely that nor-
mal splicing would take place. As far as we are aware,
the presence of normally spliced transcripts from a TA
splice donor site is unprecedented in primates.
Although the data discussed above and the absence
of this mutation in 296 unrelated, normal chromosomes
are not absolute proof that this is a causative mutation,
it would be remarkable if the mutation, which causes
truncation before the first transmembrane domain of
PS-1 (Doan et al. 1996), did not affect normal function
of this allele. If this mutation results only in a PS-1
haploinsufficiency, then this effect would be most con-
sistent if the mode of action of the mutations described
elsewhere, in mice and in cell lines, is dominant negative
and effectively reduces the activity of the wild-type allele.
However, we cannot exclude the possibility that this mu-
tation has either dominant-negative or gain-of-function
actions.
Our study demonstrates that mutations in the coding
regions and splice consensus sequences of PS-1 are rare
in cases of EOAD unselected for family history. We iden-
tified one novel splice-site mutation in two cases, one of
which had a positive family history of EOAD; however,
we could not formally show cosegregation of this mu-
tation with familial AD, owing to lack of DNA from
relatives. There have been no large studies published that
have determined the proportion of EOAD cases (unse-
lected for family history) that carry PS-1 mutations. In
one previous study, 13 clinically diagnosed, “sporadic”
EOAD cases were examined for PS-1 mutations, by use
of direct sequence analysis of cDNA, to screen the entire
coding region of eight individuals, and by genomic se-
quence analysis of only six PS-1 exons of five cases (Tan-
ahashi et al. 1996). They identified one missense mu-
tation in one individual, and the study suggested that
the frequency of PS-1 mutations in “sporadic” cases may
be low. However, this sample size was small, and the
cases were not autopsy confirmed, which is important
because clinical diagnoses of EOAD may be confounded
by a number of other heterogeneous forms of early-onset
dementia: for instance, AD accounts only for 45% of
dementia cases among individuals 40–49 years of age
and for 67% of dementia cases among individuals 50–59
years of age (Heston 1992). Although our cases had
autopsy-confirmed AD, it is possible that this brain-bank
sample may not be representative of EOAD in the
community.
We have performed a full sequence analysis of all 10
PS-1 exons and flanking splice sites in 40 cases of au-
topsy-confirmed EOAD and have found no coding mis-
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sense mutations. Similarly, only six missense mutations
were found in a random sample of 100 EOAD cases
ascertained in a population-based study in the Nether-
lands (Cruts et al., in press). This lack of variation within
the coding region indicates that missense mutations
within PS-1 are very rare in EOAD cases unselected for
family history and that future studies should also con-
sider the possibility of mutations in regulatory elements.
In conclusion, it is likely that other genetic and/or en-
vironmental factors are involved in causing the majority
of EOAD cases in the general population.
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